drugset / Trial / NCT07431853

A Study to Learn About mRNA Vaccines Against Influenza in Adults

NCT07431853 ↗

Phase 2 Recruiting 770 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body's immune response, targeting the flu virus (influenza virus). This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison. Participants will take part in this study for about 6 months, and participants will need to visit the study site at least 3 times. A blood sample will be taken at each of the 3 planned study visits and a swab from inside the nose will be taken at the first study visit.

Timeline

Start
2026-02-23
Primary completion
2027-06-22
Completion
2027-06-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator TIV1 Vaccine — Intramuscular
Comparator TIV2 Vaccine — Intramuscular
Subject Vaccine Candidate #1 Messenger RNA (mRNA) — Intramuscular
Subject Vaccine Candidate #2 Messenger RNA (mRNA) — Intramuscular
Subject Vaccine Candidate #3 Messenger RNA (mRNA) — Intramuscular
Subject Vaccine Candidate #4 Messenger RNA (mRNA) — Intramuscular
Subject Vaccine Candidate #5 Messenger RNA (mRNA) — Intramuscular
Subject Vaccine Candidate #6 Messenger RNA (mRNA) — Intramuscular

Indications

No indication recorded.